RISPERIDONE SUSTAINED RELEASE MICROSPHERE COMPOSITION
    3.
    发明申请
    RISPERIDONE SUSTAINED RELEASE MICROSPHERE COMPOSITION 审中-公开
    RISPERIDONE持续释放微球组合物

    公开(公告)号:US20170056407A1

    公开(公告)日:2017-03-02

    申请号:US15347365

    申请日:2016-11-09

    IPC分类号: A61K31/519 A61K9/00 A61K9/16

    摘要: A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.

    摘要翻译: 提供了利培酮缓释微球制剂。 微球制剂包括利培酮或9-羟基利培酮或其盐,以及具有第一未封端丙交酯 - 乙交酯共聚物和第二未封端丙交酯 - 乙交酯共聚物的聚合物共混物,其中第一未封端丙交酯 - 乙交酯共聚物是具有高的共聚物 特性粘度和第二未封端丙交酯 - 乙交酯共聚物是具有低特性粘度的共聚物。 根据本公开实施方案的缓释微球制剂适用于具有改进的稳定性的大规模工业化生产,其体内释放行为在长期储存后不会改变。

    RISPERIDONE SUSTAINED RELEASE MICROSPHERE COMPOSITION
    6.
    发明申请
    RISPERIDONE SUSTAINED RELEASE MICROSPHERE COMPOSITION 有权
    RISPERIDONE持续释放微球组合物

    公开(公告)号:US20160331752A1

    公开(公告)日:2016-11-17

    申请号:US15217696

    申请日:2016-07-22

    摘要: A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.

    摘要翻译: 提供了利培酮缓释微球制剂。 微球制剂包括利培酮或9-羟基利培酮或其盐,以及具有第一未封端丙交酯 - 乙交酯共聚物和第二未封端丙交酯 - 乙交酯共聚物的聚合物共混物,其中第一未封端丙交酯 - 乙交酯共聚物是具有高的共聚物 特性粘度和第二未封端丙交酯 - 乙交酯共聚物是具有低特性粘度的共聚物。 根据本公开实施方案的缓释微球制剂适用于具有改进的稳定性的大规模工业化生产,其体内释放行为在长期储存后不会改变。

    Risperidone sustained release microsphere composition
    7.
    发明授权
    Risperidone sustained release microsphere composition 有权
    利培酮缓释微球组成

    公开(公告)号:US09532991B2

    公开(公告)日:2017-01-03

    申请号:US15217696

    申请日:2016-07-22

    摘要: A risperidone sustained release microsphere formulation is provided. The microsphere formulation includes risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release micro sphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.

    摘要翻译: 提供了利培酮缓释微球制剂。 微球制剂包括利培酮或9-羟基利培酮或其盐,以及具有第一未封端丙交酯 - 乙交酯共聚物和第二未封端丙交酯 - 乙交酯共聚物的聚合物共混物,其中第一未封端丙交酯 - 乙交酯共聚物是具有高的共聚物 特性粘度和第二未封端丙交酯 - 乙交酯共聚物是具有低特性粘度的共聚物。 根据本公开实施方案的缓释微球制剂适用于具有改进的稳定性的大规模工业化生产,其体内释放行为在长期储存后不会改变。